Sexual Arousal Disorder

NexMed releases preliminary Femprox results from first take-home study

Published in Women's Health Weekly, August 1st, 2002

NexMed, Inc., (NEXM), a developer of innovative topical treatments based on its proprietary drug delivery technology, announced preliminary clinical results for its phase II at-home-use study for the Femprox topical cream treatment for female sexual arousal disorder (FSAD).

Femprox incorporates alprostadil, a vasodilator, with the NexACT platform drug delivery technology. The results were announced at the 97th annual meeting of the American Urological Association (AUA) in Orlando, Florida.

The multicenter phase II study was a randomized, double-blind, placebo-controlled trial, designed to investigate the efficacy and safety of Femprox cream in 98...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Women's Health Weekly

Source: Women's Health Weekly (2002-08-01)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry